On April 24, 2018, Acasti Pharma Inc. (Acasti) announced that it had entered into an underwriting agreement with Mackie Research Capital Corporation (Mackie), as sole bookrunner and underwriter, in connection with an underwritten public offering of units (Offering). On May 9, 2018, Acasti announced that it had completed the Offering which consisted in the issuance of 9,530,000 units at a price of $1.05 per unit for total aggregate proceeds to Acasti of $10 million. Each unit consisted of one common share and one common share purchase warrant, with each such warrant exercisable at any time prior to May 9, 2023 at a price of $1.31 per common share. On May 14, 2018, Acasti announced that, further to the exercise of the over-allotment option in full by Mackie, it had completed the issuance of an additional 1,429,500 units on the same terms and conditions set forth above for additional gross proceeds to Acasti of $1.5 million.
The net proceeds received from the Offering and the over-allotment option are intended to be used by Acasti for the further development of CaPre, Acasti’s lead product, and the continued advancement of Acasti’s TRILOGY Phase 3 program.
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia.
Osler, Hoskin & Harcourt LLP represented Acasti with a team consisting of Francois Paradis, Jeremy Brisset, Matthew Oliver, Jason Comerford, and Jie Chai (Corporate).